Mark Daniel Pegram, MD
Medical Oncology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 14
- 3 carriers
- Office
- 1
Offices
1 location
Plans that list them
14 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Pegram’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
14 of 14 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A46221 · Current
Licensed to practise in California · since 1989 · expires 2026-09-30 · University of North Carolina at Chapel Hill.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Internal Medicine
- American Board of Internal Medicine - Medical Oncology
Original Medicare doctor bills
$10,792
Medicare paid this office $10,792 for 28 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 15 | $3,461 | $124 |
| Return visit (30+ min) | 12 | $2,808 | $88 |
Who their Medicare patients are
28 Original Medicare patients in 2024. Average age 70 · 85 and older 0% · Health risk score 2.31. Above the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: Cancer 75% · High blood pressure 57%.
The office billed $40,981, Medicare allowed $13,545 and paid $10,792; for 93 services of 6 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 28 | 93 | 70 | 2.31 | $40,981 | $10,792 |
| 2021 | 44 | 130 | 71 | 1.97 | $43,075 | $11,243 |
| 2020 | 92 | 351 | 71 | 2.10 | $116,229 | $26,536 |
| 2019 | 89 | 286 | 71 | 2.10 | $41,435 | $20,764 |
| 2018 | 90 | 273 | 70 | 1.91 | $56,264 | $19,965 |
| 2017 | 88 | 260 | 72 | 2.03 | $51,268 | $17,778 |
| 2016 | 75 | 197 | 70 | 1.98 | $34,786 | $12,719 |
| 2015 | 104 | 381 | 70 | 1.83 | $89,028 | $25,810 |
| 2014 | 81 | 286 | 70 | 1.79 | $62,814 | $18,619 |
| 2013 | 80 | 269 | 71 | 1.51 | $68,532 | $22,280 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2021: 2 services
| Return visit (30+ min) | 31 | $7,807 | $87 |
| Short return visit (20+ min) | 13 | $1,052 | $53 |
2020: 6 services
| Return visit (30+ min) | 38 | $11,041 | $74 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 21 | $3,366 | $67 |
| Hospital discharge day management, more than 30 minutes | 21 | $2,220 | $101 |
| New patient visit (60+ min) | 12 | $1,920 | $160 |
| Short return visit (20+ min) | 31 | $1,857 | $44 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 14 | $1,814 | $130 |
2019: 3 services
| Return visit (30+ min) | 34 | $8,899 | $70 |
| New patient visit (60+ min) | 21 | $3,198 | $152 |
| Short return visit (20+ min) | 39 | $2,693 | $45 |
2018: 7 services
| Return visit (30+ min) | 30 | $5,298 | $69 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 18 | $2,746 | $65 |
| New patient visit (60+ min) | 18 | $2,566 | $143 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 14 | $2,153 | $94 |
| Short return visit (20+ min) | 26 | $1,843 | $44 |
| Hospital discharge day management, more than 30 minutes | 11 | $1,086 | $99 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 17 | $909 | $35 |
2017: 5 services
| Return visit (30+ min) | 21 | $6,011 | $66 |
| Short return visit (20+ min) | 43 | $2,878 | $41 |
| New patient visit (60+ min) | 15 | $2,255 | $150 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $1,078 | $63 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 12 | $629 | $35 |
2016: 3 services
| Return visit (30+ min) | 26 | $5,429 | $68 |
| Short return visit (20+ min) | 45 | $3,190 | $40 |
| New patient visit (60+ min) | 14 | $2,096 | $150 |
2015: 8 services
| Return visit (30+ min) | 25 | $5,137 | $67 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 20 | $3,418 | $92 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 26 | $3,342 | $64 |
| Short return visit (20+ min) | 42 | $3,207 | $41 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 18 | $3,117 | $173 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 19 | $2,349 | $35 |
| New patient visit (60+ min) | 14 | $1,846 | $132 |
| Hospital discharge day management, more than 30 minutes | 18 | $1,746 | $97 |
2014: 7 services
| Return visit (30+ min) | 21 | $4,210 | $63 |
| Short return visit (20+ min) | 42 | $3,048 | $41 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 17 | $2,242 | $64 |
| New patient visit (60+ min) | 16 | $2,113 | $132 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $1,979 | $180 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $1,848 | $92 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day at least 25 minutes | 14 | $1,527 | $35 |
2013: 8 services
| Return visit (30+ min) | 31 | $5,075 | $68 |
| Return visit (30+ min) | 20 | $3,157 | $88 |
| New patient visit (60+ min) | 16 | $2,315 | $145 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 13 | $2,268 | $174 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 11 | $1,610 | $89 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 12 | $1,552 | $62 |
| Long return visit (40+ min) | 12 | $1,242 | $96 |
| Short return visit (20+ min) | 15 | $965 | $44 |
Medicaid work
$1,312 in 2020
Medicaid paid $1,312 for 34 billed services this clinician did in 2020, up to 12 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| SBSQ HOSPITAL IP/OBS CARE MOD MDM 35 MINUTES | 34 | $1,312 |
| 2020 | 34 | 1 | 12 | $1,312 |
Drugs they prescribed that Part D paid
$78,490
Pharmacies billed $78,490 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 50) in 2024. At or below the middle of the specialty; the typical hematology-oncology clinician is at 5%.
42 generic and fewer than 11 brand-name prescriptions · $78,490 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
Year by year
| 2024 | 50 | None | 0% (0) | None | $78,490 |
| 2021 | 95 | 22 | 0% (0) | 14% | $146,505 |
| 2020 | 178 | 45 | None | 21% | $356,207 |
| 2019 | 168 | 41 | 7% (11) | 23% | $276,372 |
| 2018 | 164 | 44 | None | None | $134,934 |
| 2017 | 208 | 50 | None | 14% | $107,444 |
| 2016 | 142 | 30 | None | 19% | $127,713 |
| 2015 | 177 | 40 | 12% (22) | 23% | $188,929 |
| 2014 | 125 | 27 | None | 11% | $29,274 |
| 2013 | 133 | 29 | None | 9% | $22,227 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2021: 2 drugs
| Tamoxifen Citrate | 14 | $685 | $49 |
| Anastrozole | 21 | $254 | $12 |
2020: 3 drugs
| Tamoxifen Citrate | 22 | $1,842 | $84 |
| Anastrozole | 39 | $1,066 | $27 |
| Letrozole | 18 | $603 | $33 |
2019: 4 drugs
| Ibrance | 17 | $203,362 | $11,962 |
| Tamoxifen Citrate | 12 | $961 | $80 |
| Letrozole | 23 | $708 | $31 |
| Anastrozole | 21 | $401 | $19 |
2018: 4 drugs
| Neupogen | 11 | $50,863 | $4,624 |
| Tamoxifen Citrate | 19 | $1,303 | $69 |
| Anastrozole | 45 | $672 | $15 |
| Letrozole | 12 | $565 | $47 |
2017: 4 drugs
| Tamoxifen Citrate | 38 | $1,689 | $44 |
| Anastrozole | 38 | $530 | $14 |
| Letrozole | 11 | $414 | $38 |
| Alendronate | 19 | $134 | $7 |
2016: 3 drugs
| Exemestane | 23 | $5,312 | $231 |
| Tamoxifen Citrate | 21 | $707 | $34 |
| Anastrozole | 17 | $327 | $19 |
2015: 5 drugs
| Ibrance | 15 | $149,320 | $9,955 |
| Tamoxifen Citrate | 14 | $628 | $45 |
| Anastrozole | 33 | $617 | $19 |
| Oxycodone | 14 | $532 | $38 |
| Lorazepam | 12 | $67 | $6 |
2014: 1 drug
| Anastrozole | 57 | $1,354 | $24 |
2013: 3 drugs
| Enoxaparin | 11 | $14,489 | $1,317 |
| Anastrozole | 37 | $1,027 | $28 |
| Tamoxifen Citrate | 11 | $189 | $17 |
Money from drug and device companies
$41,055 in 2025
| 2025 | 9 | 54 | $36,135 | $41,055 |
| 2024 | 8 | 39 | $27,682 | $37,806 |
| 2023 | 10 | 50 | $35,970 | $47,990 |
| 2022 | 10 | 54 | $50,317 | $57,574 |
| 2021 | 15 | 43 | $79,010 | $79,380 |
| 2020 | 11 | 43 | $62,918 | $64,229 |
| 2019 | 14 | 69 | $31,769 | $46,348 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| AstraZeneca Pharmaceuticals LP | Enhertu | $19,170 | 19 payments
|
| Stemline Therapeutics | Orserdu | $8,775 | 9 payments
|
| Pfizer | Ibrance | $5,810 | 3 payments
|
| TerSera Therapeutics | Margenza | $4,040 | 7 payments
|
| Novartis Pharmaceuticals | Kisqali | $1,342 | 4 payments
|
| F. Hoffmann-La Roche AG | Herceptin | $1,140 | 2 payments
|
See all 53 published payments
| Novartis Pharmaceuticals | Meals · 2025-12-10 | Kisqali | $167 |
| AstraZeneca Pharmaceuticals LP | Consulting · 2025-12-10 | Enhertu | $3,280 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-12-09 | Enhertu | $64 |
| Stemline Therapeutics | Meals · 2025-12-08 | Orserdu | $87 |
| AstraZeneca Pharmaceuticals LP | Consulting · 2025-11-24 | Enhertu | $6,560 |
| AstraZeneca Pharmaceuticals LP | Travel · 2025-11-17 | Truqap | $18 |
| AstraZeneca Pharmaceuticals LP | Travel · 2025-11-17 | Truqap | $237 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-11-07 | None | $43 |
| Menarini Silicon Biosystems | Meals · 2025-10-29 | Cellsearch | $74 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-21 | None | $105 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-20 | Enhertu | $70 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-10-20 | Enhertu | $130 |
| Genentech USA | Meals · 2025-10-20 | Itovebi | $17 |
| Novartis Pharmaceuticals | Travel · 2025-10-07 | Kesimpta | $355 |
| Novartis Pharmaceuticals | Travel · 2025-10-07 | Kisqali | $784 |
| F. Hoffmann-La Roche AG | Consulting · 2025-10-01 | Herceptin | $760 |
| Stemline Therapeutics | Meals · 2025-09-13 | Orserdu | $122 |
| Stemline Therapeutics | Consulting · 2025-09-12 | Orserdu | $3,510 |
| Stemline Therapeutics | Meals · 2025-08-22 | Orserdu | $47 |
| Stemline Therapeutics | Meals · 2025-08-22 | Orserdu | $36 |
| Stemline Therapeutics | Meals · 2025-08-20 | Orserdu | $150 |
| Stemline Therapeutics | Consulting · 2025-07-25 | Orserdu | $2,340 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-07-18 | Lynparza | $46 |
| Gilead Sciences | Meals · 2025-07-18 | Trodelvy | $75 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-06-02 | None | $90 |
| Stemline Therapeutics | Meals · 2025-06-02 | Orserdu | $144 |
| Novartis Pharmaceuticals | Meals · 2025-06-01 | Kisqali | $36 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-06-01 | Enhertu | $49 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-05-29 | None | $101 |
| Stemline Therapeutics | Consulting · 2025-05-23 | Orserdu | $2,340 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-04-20 | None | $73 |
| AstraZeneca Pharmaceuticals LP | Consulting · 2025-04-08 | None | $4,305 |
| Pfizer | Consulting · 2025-04-03 | Ibrance | $3,850 |
| F. Hoffmann-La Roche AG | Consulting · 2025-04-01 | Herceptin | $380 |
| Gilead Sciences | Meals · 2025-03-30 | Trodelvy | $65 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-03-28 | Enhertu | $113 |
| Gilead Sciences | Meals · 2025-03-27 | Trodelvy | $113 |
| Pfizer | Consulting · 2025-02-26 | Ibrance | $560 |
| Pfizer | Consulting · 2025-02-20 | Ibrance | $1,400 |
| AstraZeneca Pharmaceuticals LP | Meals · 2025-02-17 | None | $57 |
| AstraZeneca Pharmaceuticals LP | Consulting · 2025-02-11 | Truqap | $2,460 |
| AstraZeneca Pharmaceuticals LP | Consulting · 2025-02-10 | None | $1,370 |
| Gilead Sciences | Meals · 2025-02-08 | Trodelvy | $85 |
| Gilead Sciences | Meals · 2025-02-06 | Trodelvy | $148 |
| Gilead Sciences | Meals · 2025-02-04 | Trodelvy | $52 |
| Gilead Sciences | Meals · 2025-01-12 | Trodelvy | $148 |
| TerSera Therapeutics | Meals · 2025-01-11 | Zoladex | $71 |
| TerSera Therapeutics | Meals · 2025-01-11 | Zoladex | $43 |
| TerSera Therapeutics | Meals · 2025-01-11 | Zoladex | $85 |
| TerSera Therapeutics | Consulting · 2025-01-06 | Margenza | $3,020 |
| TerSera Therapeutics | Travel · 2025-01-06 | Margenza | $745 |
| TerSera Therapeutics | Travel · 2025-01-06 | Margenza | $36 |
| TerSera Therapeutics | Travel · 2025-01-06 | Margenza | $41 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $37,806
| Gilead Sciences | Trodelvy | $11,126 | 15 payments
|
| AstraZeneca Pharmaceuticals LP | Enhertu | $9,318 | 8 payments
|
| Stemline Therapeutics | Orserdu | $6,886 | 5 payments
|
| Novartis Pharmaceuticals | Kisqali | $4,200 | 1 payment
|
| AstraZeneca UK | None | $3,460 | 4 payments
|
| Pfizer | Ibrance | $1,715 | 2 payments
|
| Genentech | None | $875 | 3 payments
|
| Endomagnetics | Magseed | $227 | 1 payment
|
2023: $47,990
| F. Hoffmann-La Roche AG | Herceptin | $20,034 | 6 payments
|
| Pfizer | Ibrance | $7,700 | 5 payments
|
| Gilead Sciences | Trodelvy | $6,540 | 14 payments
|
| AstraZeneca Pharmaceuticals LP | Enhertu | $5,511 | 13 payments
|
| Seagen | Tukysa | $4,105 | 3 payments
|
| Novartis Pharmaceuticals | Kisqali | $2,307 | 2 payments
|
| Stemline Therapeutics | Orserdu | $890 | 3 payments
|
| AstraZeneca UK | None | $685 | 1 payment
|
| Puma Biotechnology | Nerlynx | $145 | 2 payments
|
| Daiichi Sankyo | Enhertu | $73 | 1 payment
|
2022: $57,574
| AstraZeneca Pharmaceuticals LP | Enhertu | $23,272 | 30 payments
|
| Gilead Sciences | Trodelvy | $14,330 | 4 payments
|
| AstraZeneca UK | None | $6,850 | 4 payments
|
| Pfizer | Ibrance | $4,963 | 3 payments
|
| TerSera Therapeutics | Zoladex | $4,377 | 6 payments
|
| F. Hoffmann-La Roche AG | None | $2,310 | 2 payments
|
| Chugai Pharmaceutical Co. | Herceptin | $1,278 | 2 payments
|
| Genentech | None | $149 | 1 payment
|
| Amgen | Kanjinti | $33 | 1 payment
|
| Genentech USA | None | $12 | 1 payment
|
2021: $79,380
| AstraZeneca UK | Lynparza | $19,180 | 7 payments
|
| Pfizer | Ibrance | $14,932 | 5 payments
|
| Seagen | Tukysa | $11,628 | 7 payments
|
| AstraZeneca Pharmaceuticals LP | None | $9,190 | 11 payments
|
| Pfizer International | Ruxience | $8,348 | 2 payments
|
| Genzyme | None | $3,645 | 1 payment
|
| Novartis Pharmaceuticals | None | $3,341 | 1 payment
|
| Sanofi-Aventis U.S. | None | $2,552 | 2 payments
|
| Macrogenics | Margenza | $1,500 | 1 payment
|
| Athenex Pharmaceutical Division | None | $1,500 | 1 payment
|
| Blueprint Medicines | None | $1,400 | 1 payment
|
| F. Hoffmann-La Roche AG | None | $1,320 | 1 payment
|
| Philips Electronics North America | (8334) Igt D Peripheral | $760 | 1 payment
|
| Genentech USA | Kadcyla | $74 | 1 payment
|
| Gilead Sciences | None | $12 | 1 payment
|
2020: $64,229
| Seagen | Tukysa | $22,290 | 15 payments
|
| AstraZeneca Pharmaceuticals LP | None | $16,940 | 8 payments
|
| Samsung Bioepis Co. | Ontruzant | $6,500 | 3 payments
|
| AstraZeneca UK | Lynparza | $4,765 | 4 payments
|
| Novartis Pharmaceuticals | Piqray | $4,323 | 1 payment
|
| Gilead Sciences | None | $2,280 | 1 payment
|
| Pfizer | Ibrance | $2,195 | 2 payments
|
| Daiichi Sankyo | Enhertu | $2,055 | 1 payment
|
| Athenex Pharmaceutical Division | Oral Paclitaxel | $1,500 | 3 payments
|
| Philips Electronics North America | (8995) Molecular Pathway Diagnostics | $1,140 | 1 payment
|
| Genentech USA | Kadcyla | $241 | 4 payments
|
2019: $46,348
| F. Hoffmann-La Roche AG | Herceptin | $17,261 | 6 payments
|
| Eli Lilly and | Verzenio | $6,574 | 19 payments
|
| AstraZeneca Pharmaceuticals LP | None | $5,636 | 15 payments
|
| Novartis Pharmaceuticals | Kisqali | $3,885 | 3 payments
|
| Pfizer | None | $3,876 | 3 payments
|
| Cepheid | Genexpert | $3,076 | 2 payments
|
| Samsung Bioepis Co. | None | $2,279 | 4 payments
|
| AstraZeneca UK | None | $1,800 | 1 payment
|
| Halozyme | None | $900 | 1 payment
|
| Seattle Genetics | None | $592 | 6 payments
|
| Genentech USA | Perjeta | $314 | 5 payments
|
| Daiichi Sankyo | Enhertu | $66 | 1 payment
|
| Puma Biotechnology | Nerlynx | $50 | 1 payment
|
| Leica Microsystems | Mammotome | $40 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| AstraZeneca Pharmaceuticals LP · Medi4276 Her2 Mbc-D5760c00001 Phase 1 Clinical Trial · 2019 | Their institution | $175,989 |
| Daiichi Sankyo Inc. · Ds8201-A-U303 · 2020 | Their institution | $109,224 |
| G1 Therapeutics, Inc. · A Phase 3, Randomized, Double-Blind Study of Cosela Or Placebo in Patients Receiving First- Or Second-Line Gemcitabine and Carboplatin Chemotherapy for Locally Advanced Unresectable Or Metastatic Triple-Negative Breast Cancer (Preserve-2) · 2022 | Their institution | $83,753 |
| Daiichi Sankyo Inc. · Ds8201-A-U303 · 2021 | Their institution | $71,792 |
| Daiichi Sankyo Inc. · Enhertu · 2021 | Their institution | $34,297 |
| PFIZER INC. · A Randomized Multicenter Doubleblind Phase 3 Study of Pd0332991 Oral Cdk 46 Inhibitor Plus Letrozole Versus Placebo Plus Letrozole for the Treatment of Postmenopausal Women With Er Her2 Breast Cancer Who Have Not Received Any Prior Systemic Anti Cancer Treatment for Advanced Disease · 2022 | Their institution | $18,563 |
| PFIZER INC. · A Randomized Multicenter Doubleblind Phase 3 Study of Pd0332991 Oral Cdk 46 Inhibitor Plus Letrozole Versus Placebo Plus Letrozole for the Treatment of Postmenopausal Women With Er Her2 Breast Cancer Who Have Not Received Any Prior Systemic Anti Cancer Treatment for Advanced Disease · 2020 | Their institution | $15,417 |
| PFIZER INC. · A Randomized Multicenter Doubleblind Phase 3 Study of Pd0332991 Oral Cdk 46 Inhibitor Plus Letrozole Versus Placebo Plus Letrozole for the Treatment of Postmenopausal Women With Er Her2 Breast Cancer Who Have Not Received Any Prior Systemic Anti Cancer Treatment for Advanced Disease · 2019 | Their institution | $11,588 |
| PFIZER INC. · A Randomized Multicenter Doubleblind Phase 3 Study of Pd0332991 Oral Cdk 46 Inhibitor Plus Letrozole Versus Placebo Plus Letrozole for the Treatment of Postmenopausal Women With Er Her2 Breast Cancer Who Have Not Received Any Prior Systemic Anti Cancer Treatment for Advanced Disease · 2023 | Their institution | $9,695 |
| PFIZER INC. · A Randomized Multicenter Doubleblind Phase 3 Study of Pd0332991 Oral Cdk 46 Inhibitor Plus Letrozole Versus Placebo Plus Letrozole for the Treatment of Postmenopausal Women With Er Her2 Breast Cancer Who Have Not Received Any Prior Systemic Anti Cancer Treatment for Advanced Disease · 2021 | Their institution | $8,821 |
| F. Hoffmann-La Roche AG · An Open-Label, Multicenter, Phase II Study of High-Dose Herceptin With Perjeta in Patients With Central Nervous System Metastases From Her2 Positive Metastatic Breast An Open-Label, Multicenter, Phase II Study of High-Dose Herceptin With Perjeta in Patients With Central Nervous System Metastases From Her2 Positive Metastatic Breast Cancer · 2021 | This clinician | $3,686 |
| PFIZER INC. · Palbociclib Clinical Publication Program · 2022 | This clinician | $3,200 |
| G1 Therapeutics, Inc. · Cosela · 2023 | Their institution | $1,949 |
| Genentech, Inc. · Ipatasertib in Combination With Paclitaxel in Tnbc and Hr Breast Cancer · 2019 | This clinician | $1,650 |
| G1 Therapeutics, Inc. · Cosela · 2021 | Their institution | $1,280 |
| Daiichi Sankyo Inc. · Enhertu · 2020 | Their institution | $1,226 |
| Novartis Pharmaceuticals Corporation · Rwe Flatiron Menopausal · 2025 | This clinician | $1,206 |
| F. Hoffmann-La Roche AG · Patricia · 2020 | This clinician | $818 |
| Novartis Pharmaceuticals Corporation · Rwe Ebc Flatiron Outcomes · 2024 | This clinician | $763 |
| F. Hoffmann-La Roche AG · An Open-Label, Multicenter, Phase II Study of High-Dose Herceptin With Perjeta in Patients With Central Nervous System Metastases From Her2 Positive Metastatic Breast An Open-Label, Multicenter, Phase II Study of High-Dose Herceptin With Perjeta in Patients With Central Nervous System Metastases From Her2 Positive Metastatic Breast Cancer · 2020 | This clinician | $486 |
| Seattle Genetics, Inc. · Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib · 2019 | This clinician | $60 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1356361554
- Licence
- CA A46221California A46221: Current · expires 2026-09-30
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A462210
- Taxonomy
- Medical oncology (207RX0202X); Internal medicine (207R00000X); Federal specialty code 207RH0003X (207RH0003X); Surgical oncology (2086X0206X)
- Mailing address
- 300 Pasteur Dr Fl 1, Stanford, CA, 94305
- NPI first listed
- 2006-07-20
- NPI last updated
- 2024-04-16
- NPI record certified
- 2024-04-16
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 900 Blake Wilbur Dr, Palo Alto, CA, 94304